[go: up one dir, main page]

MX2022008100A - Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. - Google Patents

Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Info

Publication number
MX2022008100A
MX2022008100A MX2022008100A MX2022008100A MX2022008100A MX 2022008100 A MX2022008100 A MX 2022008100A MX 2022008100 A MX2022008100 A MX 2022008100A MX 2022008100 A MX2022008100 A MX 2022008100A MX 2022008100 A MX2022008100 A MX 2022008100A
Authority
MX
Mexico
Prior art keywords
chloroquine
treatment
inflammatory
clemizole
cancerous conditions
Prior art date
Application number
MX2022008100A
Other languages
English (en)
Inventor
Jeffrey S Glenn
Edward A Pham
Original Assignee
Eiger Group Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Group Int Inc filed Critical Eiger Group Int Inc
Publication of MX2022008100A publication Critical patent/MX2022008100A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen en la presente métodos para uso de R-cloroquina o clemizol o combinaciones de R-cloroquina y clemizol para el tratamiento de un sujeto que necesita del mismo. Los métodos incluyen métodos de tratamiento de afecciones inflamatorias, tratamiento de cáncer hepático o reducción del riesgo de desarrollar cáncer hepático en un sujeto. Los usos también incluyen métodos de tratamiento de esteatohepatitis no alcohólica en un sujeto.
MX2022008100A 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. MX2022008100A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562187061P 2015-06-30 2015-06-30

Publications (1)

Publication Number Publication Date
MX2022008100A true MX2022008100A (es) 2022-07-11

Family

ID=57609247

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017016681A MX394605B (es) 2015-06-30 2016-06-30 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2023003792A MX2023003792A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2022008100A MX2022008100A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017016681A MX394605B (es) 2015-06-30 2016-06-30 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2023003792A MX2023003792A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Country Status (14)

Country Link
US (3) US10688083B2 (es)
EP (1) EP3317274A4 (es)
JP (2) JP7068827B2 (es)
KR (2) KR20180032578A (es)
CN (2) CN107922404B (es)
AU (4) AU2016288699B2 (es)
CA (2) CA3178499A1 (es)
HK (1) HK1249508A1 (es)
IL (4) IL310969A (es)
MX (3) MX394605B (es)
NZ (1) NZ776616A (es)
TW (3) TWI771272B (es)
WO (1) WO2017004454A1 (es)
ZA (2) ZA201708471B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180032578A (ko) * 2015-06-30 2018-03-30 아이거 그룹 인터내셔널, 인코포레이티드 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN106831571A (zh) * 2017-02-13 2017-06-13 中卫市创科知识产权投资有限公司 一种硫酸氯喹生产工艺
US12372530B2 (en) * 2017-11-15 2025-07-29 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
CN111551645B (zh) * 2020-04-30 2022-11-08 上海中西三维药业有限公司 一种硫酸羟氯喹有关物质的检测方法及其应用
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111662229B (zh) * 2020-07-08 2023-03-24 精华制药集团南通有限公司 一种磷酸氯喹的制备工艺
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112225697B (zh) * 2020-10-16 2023-01-03 宁波大学 一种对映体纯氯喹及磷酸氯喹的制备方法
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1998017231A2 (en) * 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
WO2000066107A2 (en) * 1999-04-30 2000-11-09 Apt Pharmaceuticals, L.L.C. Antimalarian agents for the treatment of asthma
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
CA2514061A1 (en) 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
CN1761478A (zh) * 2003-02-14 2006-04-19 康宾纳特克斯公司 治疗免疫炎性疾病的联合疗法
WO2004080445A1 (en) * 2003-03-12 2004-09-23 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
JP2007509950A (ja) * 2003-10-27 2007-04-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｈｃｖ処置の組合せ剤
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SI1888033T1 (sl) * 2005-06-09 2014-06-30 Meda Ab Postopek in sestavek za zdravljenje vnetnih motenj
CN101193622A (zh) 2005-06-09 2008-06-04 比奥里波克斯公司 治疗炎性疾病的方法和组合物
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
TW200927102A (en) * 2007-09-18 2009-07-01 Univ Stanford Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
EP2188630A4 (en) * 2007-10-02 2010-11-03 Univ Rochester METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC ANSWERS TO ONCOGENIC MUTATIONS
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
CA3184380A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
KR20120039742A (ko) 2009-07-31 2012-04-25 가부시끼가이샤 스텔릭 사이세이 이카가꾸 겐뀨쇼 지방성 간염-간암 모델 동물
ES2767881T3 (es) * 2009-08-14 2020-06-18 Revivicor Inc Cerdos multi-transgénicos para el tratamiento de diabetes
US9415046B2 (en) * 2009-09-29 2016-08-16 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
WO2011051966A2 (en) * 2009-10-12 2011-05-05 Ipca Laboratories Limited Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
AU2012308491B2 (en) * 2011-09-16 2016-01-07 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
WO2013125543A1 (ja) 2012-02-20 2013-08-29 武田薬品工業株式会社 複素環化合物
US20130273003A1 (en) 2012-04-17 2013-10-17 Vertex Pharmaceuticals Incorporated Therapies for Treating Hepatitis C Virus Infection
CA2873315A1 (en) * 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
WO2013180149A1 (ja) * 2012-05-30 2013-12-05 富山化学工業株式会社 重水素化含窒素複素環カルボキサミド誘導体またはその塩
WO2014031769A2 (en) * 2012-08-21 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases associated with inflammation
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
EP3074411A2 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Nucleotides for the treatment of liver cancer
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
KR20180032578A (ko) 2015-06-30 2018-03-30 아이거 그룹 인터내셔널, 인코포레이티드 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도

Also Published As

Publication number Publication date
CA3178499A1 (en) 2017-01-05
IL279020B2 (en) 2023-07-01
CN107922404B (zh) 2021-06-29
AU2016288699B2 (en) 2020-11-26
NZ738291A (en) 2021-06-25
US20240398761A1 (en) 2024-12-05
AU2016288699A1 (en) 2018-01-18
IL279020A (es) 2020-12-31
JP2022105149A (ja) 2022-07-12
TWI830262B (zh) 2024-01-21
KR20180032578A (ko) 2018-03-30
MX2023003792A (es) 2023-04-26
IL279020B1 (en) 2023-03-01
TWI771272B (zh) 2022-07-21
WO2017004454A1 (en) 2017-01-05
NZ776616A (en) 2024-11-29
TWI881480B (zh) 2025-04-21
JP7068827B2 (ja) 2022-05-17
JP7470151B2 (ja) 2024-04-17
CN107922404A (zh) 2018-04-17
CN113274386A (zh) 2021-08-20
US10688083B2 (en) 2020-06-23
TW202317103A (zh) 2023-05-01
CA2989634C (en) 2022-12-06
IL256233A (en) 2018-02-28
IL300476A (en) 2023-04-01
MX2017016681A (es) 2018-07-06
TW202402283A (zh) 2024-01-16
KR20230129590A (ko) 2023-09-08
EP3317274A1 (en) 2018-05-09
JP2024083475A (ja) 2024-06-21
US20180200228A1 (en) 2018-07-19
MX394605B (es) 2025-03-24
IL300476B2 (en) 2024-07-01
EP3317274A4 (en) 2019-05-08
JP2018519340A (ja) 2018-07-19
BR112017028601A2 (pt) 2018-08-28
TW201717941A (zh) 2017-06-01
IL310969A (en) 2024-04-01
ZA202004136B (en) 2025-08-27
IL300476B1 (en) 2024-03-01
US12090141B2 (en) 2024-09-17
HK1249508A1 (zh) 2018-11-02
AU2023201397B2 (en) 2024-10-03
US20210052553A1 (en) 2021-02-25
AU2021201234A1 (en) 2021-03-11
CA2989634A1 (en) 2017-01-05
ZA201708471B (en) 2022-05-25
WO2017004454A8 (en) 2018-01-25
AU2024266943A1 (en) 2024-12-19
AU2023201397A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
ZA202004136B (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
ZA201708265B (en) Tigit-binding agents and uses thereof
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL276808A (en) Preparations and methods for the treatment of cancer
PL3943093T3 (pl) Zastosowanie pasteryzowanej akkermansia do leczenia nowotworu złośliwego
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
PH12018500578A1 (en) Methods of treating inflammatory diseases
SG10201809411PA (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
EA201692472A1 (ru) Соединения для лечения рака мозга
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
HUE055132T2 (hu) Virulenciában gyengített baktériumok rosszindulatú szolid tumorok kezelésére
WO2017059122A8 (en) Methods of treating and preventing amyotrophic lateral sclerosis
EP3781148A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID
IL280830A (en) Bracelets for use in cancer treatment methods
SG11202001796SA (en) Bacteria for targeting tumors and treating cancer
MX2016012244A (es) Compuestos y sus metodos de uso.
IL282692A (en) Compounds derived from madrasin, a preparation and their uses for the treatment of cancer
IL269121A (en) Usl-311 for use in the treatment of cancer